Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib Neoadjuvant Therapy in Ameloblastoma
NCT06819605Phase 3Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Mar 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of dabrafenib + trametinib and trametinib in ameloblastoma (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Recurrence-free survival rates at 5 years. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
ameloblastoma
Beyond the preview
Go deeper on NCT06819605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819605.